AR129166A1 - Bacteriófagos con actividad lítica contra mycobacterium - Google Patents
Bacteriófagos con actividad lítica contra mycobacteriumInfo
- Publication number
- AR129166A1 AR129166A1 ARP230101025A ARP230101025A AR129166A1 AR 129166 A1 AR129166 A1 AR 129166A1 AR P230101025 A ARP230101025 A AR P230101025A AR P230101025 A ARP230101025 A AR P230101025A AR 129166 A1 AR129166 A1 AR 129166A1
- Authority
- AR
- Argentina
- Prior art keywords
- activity against
- bacteriophage
- against mycobacterium
- bacteriophages
- mycobacterium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022075078 | 2022-04-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR129166A1 true AR129166A1 (es) | 2024-07-24 |
Family
ID=88518795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230101025A AR129166A1 (es) | 2022-04-28 | 2023-04-27 | Bacteriófagos con actividad lítica contra mycobacterium |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP4516898A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2023210732A1 (cg-RX-API-DMAC7.html) |
| AR (1) | AR129166A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202400783A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023210732A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4745231A1 (en) * | 2023-07-14 | 2026-05-20 | Arrowsmith Inc. | MODIFIED BACTERIOPHAGE |
| CN122060690A (zh) * | 2026-04-01 | 2026-05-19 | 深圳市百泽诺科生物技术有限公司 | 一种分枝杆菌噬菌体及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010043924A1 (en) * | 1994-04-05 | 2001-11-22 | Exponential Biotherapies, Inc. | Antibacterial therapy with bacteriophage physico-chemically altered to delay inactivation by the host defense system |
| EP2579883A1 (en) * | 2010-06-08 | 2013-04-17 | Leah Robert | Bacteriophages for use against bacterial infections |
| EP3358015A1 (en) * | 2017-02-03 | 2018-08-08 | Eligo Bioscience | Optimized vector for delivery in microbial populations |
| US11066691B1 (en) * | 2018-09-14 | 2021-07-20 | National Technology & Engineering Solutions Of Sandia, Llc | Therapeutic phages and methods thereof |
| US12576118B2 (en) * | 2019-05-21 | 2026-03-17 | University of Pittsburgh—of the Commonwealth System of Higher Education | Bacteriophages for the treatment of tuberculosis |
| CN114981408A (zh) * | 2019-11-06 | 2022-08-30 | 洛可斯生物科学公司 | Crispr cas系统和溶原性模块 |
| WO2021092362A1 (en) * | 2019-11-07 | 2021-05-14 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of specific phages for the treatment of nontuberculous mycobacteria (ntm) infections |
-
2023
- 2023-04-27 EP EP23796468.9A patent/EP4516898A4/en active Pending
- 2023-04-27 WO PCT/JP2023/016600 patent/WO2023210732A1/ja not_active Ceased
- 2023-04-27 JP JP2024518019A patent/JPWO2023210732A1/ja active Pending
- 2023-04-27 TW TW112115666A patent/TW202400783A/zh unknown
- 2023-04-27 AR ARP230101025A patent/AR129166A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202400783A (zh) | 2024-01-01 |
| EP4516898A4 (en) | 2026-05-06 |
| EP4516898A1 (en) | 2025-03-05 |
| WO2023210732A1 (ja) | 2023-11-02 |
| JPWO2023210732A1 (cg-RX-API-DMAC7.html) | 2023-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017013233A2 (pt) | bacteriófago clo-pep-1 de clostridium perfringens inovador e uso do mesmo para a inibição de proliferação de clostridium perfringens | |
| CO2017006495A2 (es) | Bacteriófago esc-cop-1 de e. coli tipo f18 productora de toxina shiga para inhibir la proliferación de e. coli tipo f18 productora de toxina shiga | |
| ES2556243T3 (es) | Agentes terapéuticos que contienen bacteriófagos | |
| Pottumarthy et al. | Nocardia veterana, a new emerging pathogen | |
| CL2019003892A1 (es) | Nuevos derivados de azaquinolina. | |
| BR112018015211A2 (pt) | indicadores biológicos | |
| MX393266B (es) | Composiciónpara usarse en terapia de microbiota | |
| Meyer et al. | In vivo efficacy of apramycin in murine infection models | |
| BR112022003129A2 (pt) | Dispositivos e métodos para a detecção de microrganismos usando bacteriófago indicador recombinante deficiente em reprodução | |
| MX2025000629A (es) | Cepas de lactobacillus salivarius y usos de las mismas | |
| BR112022026001A2 (pt) | Microrganismo com atividade intensificada de 3-metil-2-oxobutanoato hidroximetiltransferase e usos do mesmo | |
| AR075013A1 (es) | Composicion farmaceutica para proteger a un animal contra un trastorno causado por una infeccion con una bacteria que pertenece al grupo de acttinomicetes nocardioformes. uso. metodo. | |
| JPWO2023210732A5 (cg-RX-API-DMAC7.html) | ||
| Kalorey et al. | PCR analysis of Pasteurella multocida isolates from an outbreak of pasteurellosis in Indian pigs | |
| WO2020099478A3 (en) | Angptl4 oligonucleotides influencing the regulation of the fatty acid metabolism | |
| CO2020010533A2 (es) | Novedoso bacteriófago de salmonella heidelberg sal-hep-1 y su uso para inhibir el crecimiento de las bacterias de salmonella heidelberg | |
| Gomez et al. | Detection of phospholipase C in nontuberculous mycobacteria and its possible role in hemolytic activity | |
| MX2021015900A (es) | Metodos para producir bacteriofagos mutantes para la deteccion de listeria. | |
| AR128262A1 (es) | Enzima fosfolipasa c mutada y procedimiento de desgomado enzimático | |
| Sridhar et al. | First report of human infection by Agromyces mediolanus, a Gram-positive organism found in soil | |
| WO2020099482A3 (en) | Angptl 3 oligonucleotides influencing the regulation of the fatty acid metabolism | |
| Verona et al. | Bacteremia and sepsis by Arcanobacterium haemolyticum in a young immunocompetent patient | |
| WO2025019632A3 (en) | Novel rufomycin analogs as clpc1 protease modulators having activity against mycobacterium tuberculosis | |
| WO2019063792A3 (en) | OLIGONUCLEOTIDE INHIBITING CHOP EXPRESSION | |
| AR025410A1 (es) | Metodo para preparar una bacteria s. thermophilus resistente al ataque de por lo menos un bacteriofago |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |